Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R.
Bielekova B, et al. Among authors: frank ja.
Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8705-8. doi: 10.1073/pnas.0402653101. Epub 2004 May 25.
Proc Natl Acad Sci U S A. 2004.
PMID: 15161974
Free PMC article.
Clinical Trial.